Dulaglutide (Trulicity)

Dulaglutide consists of two modified human GLP-1 peptide analogs covalently linked to a human IgG4 Fc fragment, producing a long-acting GLP-1 receptor agonist for once-weekly subcutaneous administration. It is marketed as Trulicity, primarily for type 2 diabetes.^[1]

Dulaglutide was developed by Eli Lilly and approved by the FDA in 2014. Unlike most GLP-1 analogs, which extend half-life through fatty-acid albumin binding, dulaglutide uses an antibody Fc fragment fused to two GLP-1 analog peptides — a different protein-engineering strategy that achieves a similar once-weekly profile.

Mechanism is GLP-1-class standard: glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and central appetite suppression. The Fc fusion does not change the receptor pharmacology meaningfully — it changes the pharmacokinetics.^[1]

Dulaglutide's Fc-fusion structure produces a five-day half-life with predictable subcutaneous absorption. Steady state is reached in ~2–4 weeks of weekly dosing.

The peer-reviewed literature on Dulaglutide is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).

This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.

Dulaglutide is administered as a once-weekly subcutaneous injection, with a typical starting dose of 0.75 mg titrated to 1.5 mg, 3.0 mg, or 4.5 mg weekly depending on response and tolerability.

Dulaglutide is a workhorse for type 2 diabetes care, particularly in patients with elevated cardiovascular risk who benefit from REWIND-supported risk reduction. It is not the right tool when the primary target is large-magnitude weight loss — for that, semaglutide and tirzepatide remain ahead.